Tumor-Treating Fields in glioblastomas: past, present, and future
推荐理由
更新总结了TTF疗法近20年的发展历史，包括其机制研究、临床研究、现实应用等多方面的情况
| 文章简介 | |
|---|---|
| 期刊 | Cancers |
| 发表年份 | 2022 |
| DOI | 10.3390/cancers14153669 |
| 类型 | 综述 |
| 领域 | TTF疗法的发展历程 |
| 引用量 | 15 |
| 推荐信息 | |
|---|---|
| 推荐人 | 杨鑫 |
| 审核 | 胡春华 |
| 推荐小组 | TTF小组 |
摘要
Tumor-treating fields (TTFields), a noninvasive and innovative therapeutic approach, has emerged as the fourth most effective treatment option for the management of glioblastomas (GBMs), the most deadly primary brain cancer. According to on recent milestone randomized trials and subsequent observational data, TTFields therapy leads to substantially prolonged patient survival and acceptable adverse events. Clinical trials are ongoing to further evaluate the safety and efficacy of TTFields in treating GBMs and its biological and radiological correlations. TTFields is administered by delivering low-intensity, intermediate-frequency, alternating electric fields to human GBM function through different mechanisms of action, including by disturbing cell mitosis, delaying DNA repair, enhancing autophagy, inhibiting cell metabolism and angiogenesis, and limiting cancer cell migration. The abilities of TTFields to strengthen intratumoral antitumor immunity, increase the permeability of the cell membrane and the blood–brain barrier, and disrupt DNA-damage-repair processes make it a promising therapy when combined with conventional treatment modalities. However, the overall acceptance of TTFields in real-world clinical practice is still low. Given that increasing studies on this promising topic have been published recently, we conducted this updated review on the past, present, and future of TTFields in GBMs.
细分领域
< | 综述